Comments on: Spectrum Pharmaceuticals Announces Achievement of Target Enrollment in Satraplatin Phase 3 Registrational Trial (SPARC) for Second-Line Chemotherapy of Hormone Refractory Prostate Cancer

Comments on: Spectrum Pharmaceuticals Announces Achievement of Target Enrollment in Satraplatin Phase 3 Registrational Trial (SPARC) for Second-Line Chemotherapy of Hormone Refractory Prostate Cancer http://www.bioscreening.net/2005/12/05/spectrum-pharmaceuticals-announces-achievement-of-target-enrollment-in-satraplatin-phase-3-registrational-trial-sparc-for-second-line-chemotherapy-of-hormone-refractory-prostate-cancer/ Selected Bio Screening news, events and internet recources. Mon, 06 Oct 2008 13:53:30 +0000 http://wordpress.org/?v=2.0.2